Unity Biotechnology(US:UBX)2019-09-13 15:56Financial Position and Milestones - As of June 30, 2019, the company held $132 million in cash equivalents and investments, providing a runway into 2021[13] - The company anticipates an ophthalmology IND filing in early 2020 to enable multiple indications, with safety data expected in 2H 2020 and efficacy data expected in 1H 2021[105] UBX0101 - Osteoarthritis Program - Phase 1 study of UBX0101 demonstrated clear and substantial improvements in OA pain and function[9] - In the Phase 1 study, high doses of UBX0101 resulted in a -3.95 LS Mean score for NRS, compared to -1.96 for the placebo group (p<0.01)[20, 49] - A Phase 2 study of UBX0101 in OA is expected to initiate in 4Q19, with 12-week data expected in 2H20 and 24-week data expected in 1H21[9] - In Part A of the Phase 1 study, 61.1% of patients in the high-dose UBX0101 group experienced "Much Improved or Better" PGIC scores, compared to 42.9% in the placebo group[134] Ophthalmology Program - The company is developing UBX1967/1325 for age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy[36, 67] - Preclinical data shows UBX1967 reduces SASP & vascular leakage and protects retinal function in diabetic mice[98] - Senescent cell (SnC) burden increases with AMD disease stage, with the highest percentage of p16 positive cells observed in the choroid of advanced wet AMD patients[146] - Diabetic retinopathy (DR)/DME patients show SnCs in the retina and choroid[79, 147]